Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl Sells 5,250 Shares of Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 5,250 shares of Enliven Therapeutics stock in a transaction that occurred on Monday, July 29th. The stock was sold at an average price of $26.68, for a total value of $140,070.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Benjamin Hohl also recently made the following trade(s):

• On Friday, July 12th, Benjamin Hohl sold 3,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $25.07, for a total transaction of $75,210.00.
• On Thursday, June 27th, Benjamin Hohl sold 4,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $22.57, for a total value of $95,922.50.
• On Tuesday, May 28th, Benjamin Hohl sold 4,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $23.18, for a total value of $98,515.00.
• On Friday, May 3rd, Benjamin Hohl sold 1,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $22.50, for a total value of $22,500.00.

Enliven Therapeutics Trading Up 1.0 %

Shares of Enliven Therapeutics stock opened at $26.38 on Thursday. The firm has a 50-day simple moving average of $22.80 and a two-hundred day simple moving average of $19.45. Enliven Therapeutics, Inc. has a fifty-two week low of $9.80 and a fifty-two week high of $27.67.

Enliven Therapeutics (NASDAQ:ELVN) last released its quarterly earnings results on Tuesday, May 14th. The company reported ($0.54) earnings per share for the quarter, topping the consensus estimate of ($0.58) by $0.04. On average, equities research analysts forecast that Enliven Therapeutics, Inc. will post -2.26 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have commented on ELVN. Baird R W upgraded shares of Enliven Therapeutics to a “strong-buy” rating in a research note on Tuesday, June 11th. Mizuho started coverage on Enliven Therapeutics in a report on Tuesday, April 9th. They issued a “buy” rating and a $34.00 price objective for the company. Finally, Robert W. Baird started coverage on Enliven Therapeutics in a report on Tuesday, June 11th. They issued an “outperform” rating and a $32.00 price objective for the company.

Hedge Funds Weigh In On Enliven Therapeutics

Hedge funds have recently made changes to their positions in the company. SG Americas Securities LLC raised its stake in Enliven Therapeutics by 17.8% in the 4th quarter. SG Americas Securities LLC now owns 13,501 shares of the company’s stock valued at $187,000 after purchasing an additional 2,041 shares during the last quarter. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Enliven Therapeutics in the fourth quarter valued at about $66,000. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Enliven Therapeutics by 9.1% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,305 shares of the company’s stock valued at $170,000 after buying an additional 1,029 shares during the last quarter. AJOVista LLC acquired a new stake in shares of Enliven Therapeutics in the fourth quarter valued at about $28,000. Finally, EntryPoint Capital LLC acquired a new stake in shares of Enliven Therapeutics in the first quarter valued at about $167,000. Institutional investors and hedge funds own 95.08% of the company’s stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.